Cryo Cell International (CCEL) Non-Current Deffered Revenue (2010 - 2026)

Cryo Cell International has disclosed Non-Current Deffered Revenue across 17 years of filings, most recently posting $52.1 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue rose 9.15% year-over-year to $52.1 million; the TTM figure through Feb 2026 stood at $52.1 million (up 9.15% YoY), while the FY2025 annual figure was $51.0 million, up 9.49% from the prior year.
• Non-Current Deffered Revenue grew to $52.1 million in Q1 2026, from $51.0 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for CCEL reached as high as $52.1 million in Q1 2026 and fell as low as $32.2 million in Q1 2022.
• The 5-year median for Non-Current Deffered Revenue is $42.6 million (2024), against an average of $42.4 million.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue increased 15.84% — and 2026, when it climbed 9.15%.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $36.0 million in 2022, then grew by 14.41% to $41.2 million in 2023, then rose by 13.04% to $46.6 million in 2024, then grew by 9.49% to $51.0 million in 2025, then increased by 2.21% to $52.1 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $52.1 million, $51.0 million, and $49.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.